Heidelberg Pharma Gelecekteki Büyüme
Future kriter kontrolleri 2/6
Heidelberg Pharma kazanç ve gelirinin sırasıyla yıllık 31.5% ve 81.8% oranında artması tahmin edilirken, EPS'nin yıllık 31.1% oranında büyümesi bekleniyor.
Anahtar bilgiler
31.5%
Kazanç büyüme oranı
31.09%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 22.4% |
| Gelir büyüme oranı | 81.8% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 12 Feb 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • May 30
HPHA: Phase II Expansion Will Drive Future Upside Despite Going Concern Risks
Analysts now set a lower price target for Heidelberg Pharma, moving it from €6.75 to €5.50, as updated assumptions point to a very large future P/E multiple alongside tempered revenue growth expectations and a slimmer profit margin outlook. What's in the News Auditor Baker Tilly issued an unqualified opinion on the latest annual report but raised doubts about Heidelberg Pharma's ability to continue as a going concern, flagging liquidity and financing as key risk areas (Annual filing, period ending 30 Nov 2025).Anlatı Güncellemesi • May 11
HPHA: Phase II Expansion And China Milestone Will Support Future Upside
Analysts have maintained their €6.75 price target for Heidelberg Pharma, citing slightly adjusted model assumptions regarding the discount rate, revenue growth and future P/E to reflect updated expectations, while keeping their overall valuation view unchanged. What's in the News Auditor Baker Tilly issued an unqualified opinion on Heidelberg Pharma's annual report for the period ending 30 November 2025, while expressing doubt about the company's ability to continue as a going concern.Anlatı Güncellemesi • Apr 22
HPHA: Phase II Dose Selection And China Milestone Will Support Future Upside
Analysts have kept their €6.75 price target for Heidelberg Pharma unchanged, noting only minor adjustments in the discount rate and future P/E assumptions while maintaining their existing fair value view. What's in the News Heidelberg Pharma set the recommended Phase II dose for its lead candidate pamlectabart tismanitin (HDP-101) in a Phase I/IIa study for relapsed or refractory multiple myeloma, after a review found the drug was well tolerated at evaluated dose levels and a maximum tolerated dose was not reached (Product-Related Announcements).
Yeni Anlatı • Apr 16
Single Lead ADC And Funding Risks Will Dominate Near Term But Platform Potential May Emerge
Catalysts About Heidelberg Pharma Heidelberg Pharma develops antibody drug conjugates that use its proprietary Amanitin payload technology for cancer treatment. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Apr 08
HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels
Analysts have maintained their price target for Heidelberg Pharma at €6.75, citing updated assumptions that combine a very large projected revenue growth rate with an unchanged profit margin and a lower future P/E multiple. What's in the News Heidelberg Pharma plans to present preclinical data for its Amanitin-based ADC candidate HDP-103 for metastatic castration-resistant prostate cancer at the AACR Annual Meeting 2026 in San Diego, with a poster session scheduled on 21 April from 2:00 pm to 5:00 pm PDT (company announcement).
Yeni Anlatı • Apr 01
Amanitin ADC Platform And ADC Market Expansion Will Support Strong Long Term Potential
Catalysts About Heidelberg Pharma Heidelberg Pharma is a biotechnology company focused on developing antibody drug conjugates based on its proprietary Amanitin payload technology. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 24
HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels
Analysts have kept their €6.75 price target for Heidelberg Pharma broadly unchanged, citing only marginal shifts in inputs such as the discount rate, long term profit margin assumptions and future P/E, which together leave their overall valuation view effectively steady. What's in the News Huadong Medicine has reached a development milestone under its 2022 license agreement with Heidelberg Pharma, triggering a milestone payment to Heidelberg Pharma, with financial details not disclosed (company announcement).Anlatı Güncellemesi • Mar 08
HPHA: Steady Assumptions And Undervalued Outlook Will Support Future Upside
Analysts are keeping their price target for Heidelberg Pharma steady at €6.75. They cite only marginal tweaks to their discount rate and long term assumptions for revenue growth, profit margin and future P/E, rather than any shift in their core view on the stock.Anlatı Güncellemesi • Feb 21
HPHA: New Leadership And High Growth Assumptions Will Support Future Upside
Analysts have kept their price target for Heidelberg Pharma steady at €6.75, with only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions supporting this unchanged view. What's in the News The Supervisory Board revoked the appointment of Professor Andreas Pahl as Chief Executive Officer of Heidelberg Pharma AG, effective immediately (Key Developments).Anlatı Güncellemesi • Feb 07
HPHA: Leadership Transition And Stable Outlook Will Support Future Upside
Analysts have kept their price target for Heidelberg Pharma steady at €6.75. They point to only small shifts in inputs such as the discount rate and the assumed future P/E multiple as reasons for maintaining their existing view.Anlatı Güncellemesi • Jan 24
HPHA: Positive Trial Data And New Leadership Will Support Future Upside
Analysts have revised their price target for Heidelberg Pharma from €10.56 to €6.75, citing updated assumptions for revenue growth, profit margins, discount rates, and future P/E that change their assessment of the company’s risk profile and earnings potential. What's in the News The Supervisory Board revoked the appointment of Professor Andreas Pahl as Chief Executive Officer and appointed Dr Dongzhou Jeffery Liu as the new CEO with immediate effect.
Yeni Anlatı • Apr 13
ATAC Platform And HDP-101 Trials Will Advance Clinical Frontiers
Heidelberg Pharma's ATAC technology and multiple pipeline candidates offer potential for new revenue streams and long-term growth in earnings.Analiz Makalesi • Feb 16
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Dec 05
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Heidelberg Pharma AG's ( ETR:HPHA ) price-to-sales (or "P/S") ratio of 15x might make it look like a strong sell right...Analiz Makalesi • Jul 21
Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Celebrations may be in order for Heidelberg Pharma AG ( ETR:HPHA ) shareholders, with the analysts delivering a...Analiz Makalesi • Oct 16
Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Heidelberg Pharma AG ( ETR:HPHA ) shareholders will have a reason to smile today, with the analysts making substantial...Analiz Makalesi • Nov 28
Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analiz Makalesi • Mar 27
Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
The analysts covering Heidelberg Pharma AG ( ETR:HPHA ) delivered a dose of negativity to shareholders today, by making...Analiz Makalesi • Mar 15
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, Heidelberg Pharma...Analiz Makalesi • Jan 17
Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Heidelberg Pharma AG ( ETR:HPHA ) shareholders might be concerned after seeing the share price drop 14% in the last...Analiz Makalesi • Dec 14
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 11/30/2027 | 20 | -23 | N/A | N/A | 2 |
| 11/30/2026 | 11 | -24 | N/A | N/A | 2 |
| 2/28/2026 | 3 | -41 | -29 | -29 | N/A |
| 11/30/2025 | 1 | -42 | -32 | -32 | N/A |
| 8/31/2025 | 3 | -26 | -32 | -32 | N/A |
| 5/31/2025 | 4 | -23 | -27 | -27 | N/A |
| 2/28/2025 | 7 | -21 | -28 | -27 | N/A |
| 11/30/2024 | 7 | -19 | -30 | -30 | N/A |
| 8/31/2024 | 8 | -19 | -30 | -30 | N/A |
| 5/31/2024 | 10 | -13 | -33 | -32 | N/A |
| 2/29/2024 | 9 | -18 | -34 | -34 | N/A |
| 11/30/2023 | 10 | -20 | -35 | -34 | N/A |
| 8/31/2023 | 9 | -22 | -35 | -34 | N/A |
| 5/31/2023 | 11 | -27 | -35 | -34 | N/A |
| 2/28/2023 | 20 | -19 | -14 | -13 | N/A |
| 11/30/2022 | 19 | -20 | -9 | -9 | N/A |
| 8/31/2022 | 17 | -21 | -9 | -8 | N/A |
| 5/31/2022 | 13 | -22 | -7 | -6 | N/A |
| 2/28/2022 | 2 | -27 | -28 | -27 | N/A |
| 11/30/2021 | 2 | -26 | -28 | -27 | N/A |
| 8/31/2021 | 2 | -25 | -25 | -23 | N/A |
| 5/31/2021 | 7 | -22 | -24 | -23 | N/A |
| 2/28/2021 | 7 | -20 | -21 | -20 | N/A |
| 11/30/2020 | 9 | -18 | -19 | -18 | N/A |
| 8/31/2020 | 10 | -17 | -18 | -17 | N/A |
| 5/31/2020 | 7 | -15 | -12 | -11 | N/A |
| 2/29/2020 | 8 | -12 | -11 | -10 | N/A |
| 11/30/2019 | 7 | -10 | N/A | -9 | N/A |
| 8/31/2019 | 7 | -10 | N/A | -9 | N/A |
| 5/31/2019 | 6 | -11 | N/A | -12 | N/A |
| 2/28/2019 | 4 | -12 | N/A | -10 | N/A |
| 11/30/2018 | 4 | -12 | N/A | -10 | N/A |
| 8/31/2018 | 4 | -11 | N/A | -10 | N/A |
| 5/31/2018 | 3 | -11 | N/A | -8 | N/A |
| 2/28/2018 | 2 | -11 | N/A | -9 | N/A |
| 11/30/2017 | 2 | -11 | N/A | -8 | N/A |
| 8/31/2017 | 2 | -10 | N/A | -7 | N/A |
| 5/31/2017 | 2 | -8 | N/A | -8 | N/A |
| 2/28/2017 | 2 | -7 | N/A | -7 | N/A |
| 11/30/2016 | 2 | -6 | N/A | -7 | N/A |
| 8/31/2016 | 2 | -7 | N/A | -6 | N/A |
| 5/31/2016 | 2 | -7 | N/A | -5 | N/A |
| 2/29/2016 | 2 | -7 | N/A | -5 | N/A |
| 11/30/2015 | 3 | -7 | N/A | -5 | N/A |
| 8/31/2015 | 3 | -5 | N/A | -4 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: HPHA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Kazançlar ve Piyasa: HPHA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Yüksek Büyüme Kazançları: HPHA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Gelir ve Pazar: HPHA şirketinin gelirinin (yıllık 81.8% ) German pazarından (yıllık 6.7% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: HPHA şirketinin gelirinin (yıllık 81.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: HPHA 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/04 04:23 |
| Gün Sonu Hisse Fiyatı | 2026/06/04 00:00 |
| Kazançlar | 2026/02/28 |
| Yıllık Kazançlar | 2025/11/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Heidelberg Pharma AG 9 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Bruno Bulic | Baader Helvea Equity Research |
| Christian Weiz | Baader Helvea Equity Research |
| Robin Davison | Edison Investment Research |